Pfizer
Pfizer’s Fragmin injection secures FDA approval in paediatric symptomatic venous thromboembolism
May 17, 2019Medical Communications, Sales and Marketing FDA, Fragmin, Pfizer, pharma
The FDA has announced its approval of Pfizer’s anticoagulant injection Fragmin (dalteparin sodium) for subcutaneous use as a treatment to …
Pfizer’s abrocitinib smashes primary and secondary endpoints at Phase 3 in atopic dermatitis
May 16, 2019Research and Development Pfizer, abrocitinib, atopic dermatitis, pharma
Pfizer has lifted the curtain on new Phase 3 data for its Janus kinase 1 (JAK1) inhibitor abrocitinib, revealing that …
Pfizer & Merck’s Inlyta combo becomes first FDA-approved anti-PD-L1 therapy for kidney cancer
May 15, 2019Research and Development, Sales and Marketing FDA, Merck KGaA, Pfizer, inylta, pharma, renal cell carcinoma
The FDA has approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the treatment of advanced renal cell carcinoma (RCC). …
Pfizer scores conditional European approval in ALK-positive lung cancer with Lorviqua
May 8, 2019Research and Development Cancer, Europe, Lorviqua, NSCLC, Pfizer, lung cancer, pharma
Pfizer’s Lorviqua (lorlatinib), or Lorbrena as it is known in the US, Canada and Japan, has just been awarded conditional …
FDA approves first two drugs for transthyretin amyloid cardiomyopathy
May 7, 2019Manufacturing and Production, Sales and Marketing FDA, Pfizer, US, Vyndamax, Vyndaqel, pharma
The FDA has approved its first two therapies for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), …
Keytruda/Inlyta combo scores FDA approval in advanced kidney cancer
April 23, 2019Manufacturing and Production, Sales and Marketing FDA, MSD, Pfizer, Sutent, inlyta, keytruda, pharma
MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) has secured another approval from the FDA, this time as a first-line treatment in combination …
Pfizer immune-oncology leader joins Aduro Biotech as new CMO
April 23, 2019Manufacturing and Production Aduro Biotech, Cancer, Pfizer, immuno-oncology, immunotherapy, oncology
Pfizer’s vice president and head of immune-oncology clinical development has joined Aduro Biotech as the company’s new Chief Medical Officer, …
Pfizer unveils new Phase 2 data on 20-valent pneumococcal conjugate vaccine
April 15, 2019Research and Development, Sales and Marketing Pfizer, Streptococcus pneumoniae, Vaccine, pharma
Pfizer has revealed new Phase 2 data on its 20-valent pneumococcal conjugate vaccine candidate, known as PF-06482077 (20vPnC), detailing the …
Top Ten most popular articles on Pharmafile.com this week!
April 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior
This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile …
FDA approves Pfizer’s Ibrance for advanced male breast cancer
April 5, 2019Medical Communications, Sales and Marketing Cancer, FDA, Pfizer, breast cancer, ibrance, male breast cancer, pharma
The FDA has chosen to expand the indications of Pfizer’s Ibrance (palbociclib), the company announced, approving the CDK4/6 inhibitor in …
European approval for Pfizer’s Vizimpro in first-line non-small cell lung cancer
April 4, 2019Sales and Marketing Cancer, Europe, Pfizer, Vizimpro, lung cancer, non small cell lung cancer, non-small cell lung cancer, pharma
The European Commission has awarded marketing approval to Pfizer’s tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib), it has emerged, as a …
Sangamo and Pfizer’s gene therapy increases FVIII activity in severe haemophilia A in early study
April 3, 2019Research and Development, Sales and Marketing Pfizer, Sangamo, haemophilia, pharma
Sangamo Therapeutics and Pfizer have unveiled new Phase 1/2 data for their jointly developed investigational gene therapy SB-525, demonstrating that …
Top Ten most popular articles on Pharmafile.com this week!
March 22, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Biogen, Eisai, FDA, Merck, NICE, Pfizer, Roche, Sandoz
This week was a bad week for clinical trials. While the FDA put Roche and AbbVie’s multiple myeloma trial on …
Pfizer and Merck discontinue Phase 3 avelumab ovarian cancer trial
March 20, 2019Research and Development Merck KGaA, Pfizer, javelin, oncology, ovarian cancer
Pfizer and Merck KGaA have chosen to discontinue the Phase 3 JAVELIN trial looking into avelumab in combination with chemotherapy …
Pfizer CEO Ian Read’s pay packet cut from $27.9m to $19.5m
March 15, 2019Medical Communications CEO, Ian Read, Pfizer, compensation, pay packet, salary
Ian Read has seen his total compensation cut from a sum of $27.9 million in 2018 to $19.5 million this …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
